News

Novartis recently announced that the company’s once-a-day Ultibro® Breezhaler® (indacaterol/glycopyrronium), a dual bronchodilator, has meet its primary endpoint in a Phase 3 clinical trial (FLAME trial), showing superior efficacy when compared to twice-a-day Seretide® (salmeterol/fluticasone) in reducing mild, moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations. The IGNITE Phase…

Sunovion Pharmaceuticals together with the COPD Foundation has launched a novel video series, called Reel COPD, sharing first-hand stories from patients and caregivers. The videos, three of which are already available at COPDTogether.com, provide personal insights into life with a progressive and chronic illness, and are intended to motivate and help guide others dealing with the…

Verona Pharma plc, a United Kingdom-based biopharmaceutical company dedicated to therapies for respiratory disorders, recently announced the completion of the patient enrollment phase in two Phase 2a clinical trials assessing the company’s product RPL554. RPL554 is a “first-in-class” inhaled drug under development for respiratory conditions such as chronic obstructive…

In a recent study entitled “DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease,” researchers propose that cigarette smoke induces damage to telomeres, and that telomere dysfunction promotes lung impairment and decline in chronic obstructive pulmonary disease (COPD) patients. The study was…

Researchers at Ege University in Turkey recently showed that non-invasive ventilation (NIV) and supplemental oxygen can offer clinical benefits to patients with severe chronic obstructive pulmonary disease (COPD) during exercise training. The results were presented at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28…

In a new study, researchers at the Hospital of Anhui Medical University explored the phenotypes of viruses and bacteria involved in chronic obstructive pulmonary disease (COPD) pathogenesis, and their impact on the length of stay (LOS) in hospitalized patients and on the COPD Assessment Test (CAT) Scale. The research paper,…

During the recent American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal, Canada, Boehringer Ingelheim Pharmaceuticals, Inc. presented several positive post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 clinical trials. Phase III TONADO 1&2 (NCT01431274/NCT01431287) and OTEMTO® 1&2 studies evaluated the efficacy and safety of tiotropium/olodaterol delivered via the…

GlaxoSmithKline recently announced in a press release positive data from two head-to-head trials comparing the safety and efficacy of its product Incruse® Ellipta® (umeclidinium) to two available bronchodilator therapies, tiotropium (trial 201316) and glycopyrronium (trial 201315), as a treatment option for patients with chronic obstructive pulmonary disease (COPD).

Results from a recent study published in the CHEST Journal showed that yoga is a cost-effective form of rehabilitation that is as effective as standard progressive muscle relaxation (PMR) programs for patients with chronic obstructive pulmonary disease (COPD). According to the study, yoga programs can be adopted as…

In a recent study published in the journal Telemedicine and eHealth, a team led by researchers from Temple University in Philadelphia showed that a digital health application for reporting chronic obstructive pulmonary disease (COPD) symptoms can facilitate early detection and treatment of disease exacerbations. COPD is…